1. Integrated molecular signaling involving mitochondrial dysfunction and alteration of cell metabolism induced by tyrosine kinase inhibitors in cancer
   María A. Rodríguez-Hernández et al, 2020, Redox Biology CrossRef
2. Lenvatinib: A narrative drug review
   Alok Goel et al, 2021, Cancer Research, Statistics, and Treatment CrossRef
3. Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice
   Rong Wang et al, 2019, Molecular Cancer Therapeutics CrossRef
4. Inverse in silico–in vitro fishing of unexpected paroxetine kinase targets from tumor druggable kinome
   Weiyan Zhou et al, 2020, Journal of Molecular Modeling CrossRef
5. Safety and Efficacy of Sorafenib and Lenvatinib in Patients Who Underwent Surgery or Whole-Brain Radiotherapy for Brain Metastasis of Hepatocellular Carcinoma
   Pang-Shuo Perng et al, 2022, Journal of Clinical Medicine CrossRef
6. Brain Metastases From Differentiated Thyroid Carcinoma: Prevalence, Current Therapies, and Outcomes
   Cristiane J Gomes-Lima et al, 2019, Journal of the Endocrine Society CrossRef
7. Molecular mechanisms of drug resistance of glioblastoma. Part 1: ABC family proteins and inhibitors
   Alexander N. Chernov et al, 2021, Medical academic journal CrossRef
8. Lenvatinib for thyroid cancer treatment: discovery, pre-clinical development and clinical application
   Rosa Maria Paragliola et al, 2020, Expert Opinion on Drug Discovery CrossRef
9. CtBP2 interacts with ZBTB18 to promote malignancy of glioblastoma
   Liang Chen et al, 2020, Life Sciences CrossRef
10. Applications of promiscuity of FDA-approved kinase inhibitors in drug repositioning and toxicity
    Meghana Korikani et al, 2023, Toxicology and Applied Pharmacology CrossRef